Vericel Corp (VCEL) Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced therapies for sports medicine (MACI) and severe burn care (Epicel, NexoBrid). The company operates in a single reportable segment and is headquartered in Cambridge, MA.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $67.5 million | $57.9 million | $183.3 million | $161.8 million |
| Gross Profit | $49.6 million | $41.7 million | $132.5 million | $113.6 million |
| Gross Margin | 73.5% | 71.9% | 72.3% | 70.2% |
| Net Income (Loss) | $5.1 million | $(0.9) million | $(6.7) million | $(9.4) million |
| Diluted EPS | $0.10 | $(0.02) | $(0.13) | $(0.19) |
| Operating Cash Flow (YTD) | $36.9 million (2025) vs $35.9 million (2024) | |||
| Cash & Investments (Sept 30, 2025) | $185.0 million ($100.4M Cash + $84.6M Investments) | |||
| Debt | $0 outstanding borrowings on $150M Revolver |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 16.6% year-over-year, driven by a 24.6% increase in MACI revenue and a 37.7% increase in NexoBrid revenue. This growth was partially offset by a 14.8% decline in Epicel revenue.
- Profitability: The company reported a net income of $5.1 million in Q3 2025, a significant turnaround from a net loss of $0.9 million in Q3 2024. Operating income turned positive at $3.5 million compared to a loss of $2.5 million in the prior year.
- Expense Management: Selling, General, and Administrative (SG&A) expenses increased 4.7% in Q3 and 14.7% YTD, primarily due to higher headcount, stock-based compensation, and facility costs associated with the new Burlington, MA manufacturing site.
- Liquidity: Cash and cash equivalents increased to $100.4 million from $74.5 million at year-end 2024. Restricted cash decreased as escrow funds for the Burlington facility were disbursed.
Outlook, Risks, and Management Commentary
- MACI Arthro Expansion: Following FDA approval in August 2024, MACI Arthro (arthroscopic delivery) is driving volume growth. Management expanded the target surgeon base from 5,000 to 7,000.
- Manufacturing: The new Burlington, MA facility is substantially complete. Once validated, it will become the primary manufacturing site for MACI and Epicel.
- Geopolitical Risks: NexoBrid is manufactured by MediWound in Israel. Management monitors Middle East conflicts but currently maintains ample U.S. inventory and does not anticipate material supply disruption.
- Regulatory Risks: The filing highlights risks related to potential FDA staffing reductions and budget constraints under the new U.S. administration, which could delay reviews for the MACI Ankle clinical trial expected to begin enrollment in late 2025.
- Liquidity Outlook: Management expects current cash, investments, and borrowing capacity to support operations for at least 12 months.
Investor Verification Checklist
- Verify the sustainability of MACI revenue growth following the MACI Arthro launch and the impact of the expanded surgeon base.
- Monitor the timeline for validation and qualification of the Burlington, MA manufacturing facility.
- Assess the impact of potential FDA regulatory delays on the MACI Ankle clinical trial and future label expansion.
- Review the stability of the NexoBrid supply chain given ongoing geopolitical tensions in Israel.
- Track the trajectory of Epicel revenue, which has declined 21.7% YTD, to determine if this is a temporary fluctuation or a structural shift.